Corcept Therapeutics to Present Data at the 2019 American Association of Clinical Endocrinologists’ 28th Annual Congress
April 18 2019 - 4:05PM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of drugs to treat severe metabolic, oncologic and psychiatric
disorders by modulating the effects of the stress hormone cortisol,
today announced its roster of presentations at the 28th Annual
Congress of the American Association of Clinical Endocrinologists
(AACE), taking place in Los Angeles, California from April 24 –
28th.
Data presented will include an oral and poster
presentation on Saturday, April 27th of results from the Phase 2
trial of Corcept’s proprietary, selective cortisol modulator,
relacorilant, to treat patients with hypercortisolism. “We
are excited to present final efficacy and safety data from
relacorilant’s successful Phase 2 trial,” said Joseph K. Belanoff,
M.D., Corcept’s Chief Executive Officer, “which we hope to confirm
in our ongoing Phase 3 trial, GRACE.”
Thursday, April 25th |
Improvement in Muscle Strength and Psychiatric Symptoms in
a Patient with Persistent Cushing Disease Treated with
MifepristoneT. Yacoub; K. Palaniswamy |
e-Poster
PresentationTime: 1:00 - 1:30 pmMonitor Number: 34 |
Mifepristone Provides Beneficial Clinical Improvement in
Two Cushing DiseaseCases in a Community
Endocrinology PracticeC. Iweha; D. Chavez |
e-Poster PresentationTime: 1:30 - 2:00 pmMonitor Number: 1 |
Clinical Consequences of an Untreated Cortisol-Producing
Adrenal Adenoma: A 10-Year History T. Jerkins; R.
Jerkins; R. Ray |
e-Poster PresentationTime: 1:00 - 1:30 pmMonitor Number: 17 |
Prevalence of Hypercortisolism in Patients with Type 2
Diabetes Mellitus with Incidentally Found Adrenal Adenomas: An
Interim AnalysisI. Sachmechi; M. Alkomos; P.
Zarghamravanbakhsh; R. Mahendhar; K. Palaniswamy |
e-Poster PresentationTime: 1:30 - 2:00 pmMonitor Number: 9 |
Saturday, April 27th |
Efficacy
and Safety of the Selective Glucocorticoid Receptor Modulator,
Relacorilant (up to 400 mg/day), in Patients with Endogenous
Hypercortisolism: Results from an Open-Label Phase 2
StudyR. Pivonello; A. Kargi; N. Ellison; A. Moraitis; M.
Terzolo |
Oral Poster
PresentationTime: 10:15 - 10:30 amLocation: Petree Hall |
Hypercortisolism
Hypercortisolism, often referred to as Cushing’s
syndrome, is caused by excessive activity of the hormone cortisol.
Endogenous Cushing’s syndrome is an orphan disease that most often
affects adults aged 20-50. In the United States, an estimated
20,000 patients have Cushing’s syndrome, with about 3,000 new
patients being diagnosed each year. Symptoms vary, but most people
experience one or more of the following manifestations: high blood
sugar, diabetes, high blood pressure, upper-body obesity, rounded
face, increased fat around the neck, thinning arms and legs, severe
fatigue and weak muscles. Irritability, anxiety, cognitive
disturbances and depression are also common. Hypercortisolism can
affect every organ system in the body and can be lethal if not
treated effectively.
About Corcept Therapeutics Incorporated
Corcept is a commercial-stage company engaged in
the discovery and development of drugs that treat severe metabolic,
oncologic and psychiatric disorders by modulating the effects of
the stress hormone cortisol. Corcept’s approved product, Korlym®,
was the first FDA-approved treatment for patients with Cushing’s
syndrome. Korlym modulates the activity of cortisol at the
glucocorticoid receptor, one of the two receptors to which cortisol
binds. Corcept has discovered a large portfolio of proprietary
compounds that selectively modulate the effects of cortisol but not
progesterone. Corcept owns extensive United States and foreign
intellectual property covering the composition of its selective
cortisol modulators and in the use of cortisol modulators,
including Korlym, to treat a wide variety of serious disorders.
CONTACT:Christopher S. James,
MDDirector, Investor RelationsCorcept
Therapeutics650-684-8725cjames@corcept.comwww.corcept.com
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Sep 2023 to Sep 2024